Heparin centralized procurement not being selected has affected product sales. Hebei Changshan Biochemical Pharmaceutical expects a net loss in 2024 | Quick read announcement.

In 2024, Hebei Changshan Biochemical Pharmaceutical is expected to continue to report a loss in net income, but with a significant narrowing compared to 2023; previously, the company stated that there are currently no plans to conduct clinical trials for the weight loss indication of Abengutai injection.

cls.cnJan 23 08:32 ET

Third quarter dividends change to pre-spring festival dividends? Fulejia and others rely on "spring festival red envelopes" to attract attention | Quick reading of announcements.

① Following three squirrels inc., Fu Er Jia announced a dividend plan before the Spring Festival; ② The so-called dividends before the Spring Festival from the two companies are essentially third quarter dividends; ③ Both companies operate within the consumer sector and are facing certain pressures; ④ This operation may be a response to the policy call for "dividends before the Spring Festival."

cls.cnDec 3, 2024 09:05 ET

The State-owned Assets Supervision and Administration Commission and the National Development and Reform Commission jointly issued significant venture capital policies, and the equity market is expected to enter a period of development and prosperity.

① The State-owned Assets Supervision and Administration Commission (SASAC) and the National Development and Reform Commission jointly issued policy measures to promote the high-quality development of venture capital funds by central enterprises, supporting these enterprises to initiate and establish venture capital funds, focusing on early-stage, small-scale, long-term investments, and hard technology. ② Citic sec research reports indicate that in the context of the secondary market entering a valuation expansion cycle, with the increasing linkage effect between the primary and secondary markets, the equity market will also move towards a prosperous period of high-quality development.

cls.cnDec 2, 2024 19:02 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27, 2024 09:29 ET

Aimer Group: Cost reduction and efficiency improvement cannot stop the decline in demand. The end of the third quarter is a conventional high point for inventory｜Directly hitting the earnings conference.

① Aimer Co., Ltd. stated at the earnings conference that the end of the third quarter is a relative high point of inventory in the company's regular operation, mainly for stocking up for the sales peak in the fourth quarter; ② The main reason for the loss in the third quarter is the significant drop in market demand, and the company's revenue decline is substantial, while the efforts to increase efficiency and reduce costs could not offset the impact of the revenue decrease; ③ The company's sportswear sector is still in its infancy, and its contribution to performance is not significant.

cls.cnNov 19, 2024 04:05 ET

Zhangzhou pientzehuang pharmaceutical "curved" acquisition of Fujian cosunter pharmaceutical? The innovative drugs sector sees the reappearance of traditional chinese medicine industry players | Read the announcement quickly.

Fujian Cosunter Pharmaceutical announced that the Yuanshan Fund intends to become a shareholder with more than 5% stake in the company through a transfer payment of nearly 0.2 billion yuan. The partners of the Yuanshan Fund consist of a wholly state-owned company and a wholly-owned subsidiary of zhangzhou pientzehuang pharmaceutical, among which the investment from zhangzhou pientzehuang pharmaceutical is the largest limited partner in the fund.

cls.cnNov 15, 2024 11:14 ET